Fosmanogepix

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Fosmanogepix
DrugBank Accession Number
DB15183
Background

Fosmanogepix is under investigation in clinical trial NCT03604705 (An Efficacy and Safety Study of APX001 in Non-Neutropenic Patients With Candidemia).

Type
Small Molecule
Groups
Investigational
Structure
Weight
Average: 468.406
Monoisotopic: 468.11987141
Chemical Formula
C22H21N4O6P
Synonyms
  • [2-amino-3-[3-[[4-(2-pyridyloxymethyl)phenyl]methyl]isoxazol-5-yl]pyridin-1-ium-1-yl]methyl hydrogen phosphate
  • Fosmanogepix
External IDs
  • APX-001
  • APX001

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
1XQ871489P
CAS number
2091769-17-2
InChI Key
JQONJQKKVAHONF-UHFFFAOYSA-N
InChI
InChI=1S/C22H21N4O6P/c23-22-19(4-3-11-26(22)15-31-33(27,28)29)20-13-18(25-32-20)12-16-6-8-17(9-7-16)14-30-21-5-1-2-10-24-21/h1-11,13,23H,12,14-15H2,(H2,27,28,29)
IUPAC Name
2-amino-1-[(hydrogen phosphonatooxy)methyl]-3-[3-({4-[(pyridin-2-yloxy)methyl]phenyl}methyl)-1,2-oxazol-5-yl]pyridin-1-ium
SMILES
NC1=C(C=CC=[N+]1COP(O)([O-])=O)C1=CC(CC2=CC=C(COC3=NC=CC=C3)C=C2)=NO1

References

General References
Not Available
ChemSpider
64853722
ChEMBL
CHEMBL4297591
Wikipedia
Fosmanogepix

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentCandidemia1
2CompletedTreatmentCandidemia / Candidiasis / Invasive Candidiasis1
2TerminatedTreatmentInvasive Fungal Infections1
1Active Not RecruitingBasic ScienceHepatic Impairment1
1CompletedBasic ScienceInvasive Fungal Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0209 mg/mLALOGPS
logP1.13ALOGPS
logP-4.2Chemaxon
logS-4.4ALOGPS
pKa (Strongest Acidic)0.44Chemaxon
pKa (Strongest Basic)3.87Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count7Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area147.64 Å2Chemaxon
Rotatable Bond Count9Chemaxon
Refractivity119.86 m3·mol-1Chemaxon
Polarizability46.35 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleYesChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0009100000-3fca59ad62078dc0df38
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9000300000-dde8b3a569c57a56bd28
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-004l-9000000000-08292d0601261cd87f52
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-00di-0039200000-1aa4e0c6df8696b2e188
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-004i-9150100000-4520543fc5ae4d0d501d
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-08fu-0691200000-d80f4ed8de550064490c
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
Not Available

Drug created at May 20, 2019 14:57 / Updated at May 04, 2023 06:06